» Articles » PMID: 38812478

Impact of the 2022 Pulmonary Hypertension Definition on Haemodynamic Classification and Mortality in Patients with Aortic Stenosis Undergoing Valve Replacement

Overview
Date 2024 May 30
PMID 38812478
Authors
Affiliations
Soon will be listed here.
Abstract

Aims: With the 2022 pulmonary hypertension (PH) definition, the mean pulmonary artery pressure (mPAP) threshold for any PH was lowered from ≥25 to >20 mmHg, and the pulmonary vascular resistance (PVR) value to differentiate between isolated post-capillary PH (IpcPH) and combined pre- and post-capillary PH (CpcPH) was reduced from >3 Wood units (WU) to >2 WU. We assessed the impact of this change in the PH definition in aortic stenosis (AS) patients undergoing aortic valve replacement (AVR).

Methods And Results: Severe AS patients ( = 503) undergoing pre-AVR cardiac heart catheterization were classified according to both the 2015 and 2022 definitions. The post-AVR mortality [median follow-up 1348 (interquartile range 948-1885) days] was assessed. According to the 2015 definition, 219 (44% of the entire population) patients had PH: 63 (29%) CpcPH, 125 (57%) IpcPH, and 31 (14%) pre-capillary PH. According to the 2022 definition, 321 (+47%) patients were diagnosed with PH, and 156 patients (31%) were re-classified: 26 patients from no PH to IpcPH, 38 from no PH to pre-capillary PH, 38 from no PH to unclassified PH, 4 from pre-capillary PH to unclassified PH, and 50 from IpcPH to CpcPH (CpcPH: +79%). With both definitions, only the CpcPH patients displayed increased mortality (hazard ratios ≈ 4). Among the PH-defining haemodynamic components, PVR was the strongest predictor of death.

Conclusion: In severe AS, the application of the 2022 PH definition results in a substantially higher number of patients with any PH as well as CpcPH. With either definition, CpcPH patients have a significantly increased post-AVR mortality.

Citing Articles

The Monocrotaline Rat Model of Right Heart Disease Induced by Pulmonary Artery Hypertension.

Krstic A, Jones T, Power A, Ward M Biomedicines. 2024; 12(9).

PMID: 39335458 PMC: 11428269. DOI: 10.3390/biomedicines12091944.

References
1.
Ubben T, Frerker C, Fujita B, Rosenkranz S, Pfister R, Baldus S . Association of pulmonary hypertension with the outcome in patients undergoing edge-to-edge mitral valve repair. Heart. 2024; 110(11):800-807. DOI: 10.1136/heartjnl-2023-323473. View

2.
Guder G, Reiter T, Fette G, Hundertmark M, Frantz S, Morbach C . Diagnosing post-capillary hypertension in patients with left heart disease: impact of new guidelines. Clin Res Cardiol. 2023; . DOI: 10.1007/s00392-023-02290-5. View

3.
Galie N, Humbert M, Vachiery J, Gibbs S, Lang I, Torbicki A . 2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension: The Joint Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS):.... Eur Heart J. 2015; 37(1):67-119. DOI: 10.1093/eurheartj/ehv317. View

4.
Maron B, Brittain E, Hess E, Waldo S, Baron A, Huang S . Pulmonary vascular resistance and clinical outcomes in patients with pulmonary hypertension: a retrospective cohort study. Lancet Respir Med. 2020; 8(9):873-884. PMC: 8219057. DOI: 10.1016/S2213-2600(20)30317-9. View

5.
Cardaioli F, Fovino L, Fabris T, Masiero G, Arturi F, Trevisanello A . Updated definition of pulmonary hypertension and outcome after transcatheter aortic valve implantation. Heart. 2023; 110(1):27-34. DOI: 10.1136/heartjnl-2023-322881. View